Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2018-11-27
- Target Recruit Count
- 4
- Registration Number
- NCT02494713
- Locations
- 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States
Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer
- Conditions
- Stage IV Prostate Cancer
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2021-11-12
- Target Recruit Count
- 12
- Registration Number
- NCT02489357
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Dysregulation of FSH in Obesity: Functional and Statistical Analysis
- Conditions
- ObesityFertility
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 99
- Registration Number
- NCT02478775
- Locations
- 🇺🇸
University of Colorado Clinical and Translational Research Center, Aurora, Colorado, United States
Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists
- Conditions
- Cardiovascular DiseasesProstatic Neoplasms
- Interventions
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 80
- Registration Number
- NCT02475057
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇮🇱Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel
Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT02468284
- Locations
- 🇨🇳
Peking University Third Hospital (there may be other sites in this country), Beijing, China
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
- Conditions
- Stage I Prostate CancerStage IIA Prostate CancerProstate AdenocarcinomaStage III Prostate CancerStage IIB Prostate Cancer
- Interventions
- Radiation: Internal Radiation TherapyOther: Laboratory Biomarker AnalysisOther: Quality-of-Life Assessment
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 146
- Registration Number
- NCT02346253
- Locations
- 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States
Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2019-08-29
- Target Recruit Count
- 20
- Registration Number
- NCT02324998
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge University Hospitals Foundation Trust,, Cambridge, Cambridgeshire, United Kingdom
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
- Conditions
- Stage III Prostate CancerRecurrent Prostate CancerAdenocarcinoma of the ProstateStage IV Prostate Cancer
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 19
- Registration Number
- NCT02278185
- Locations
- 🇺🇸
University of Colorado Health - Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
- Conditions
- Advanced Prostate Cancer
- Interventions
- Drug: LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 461
- Registration Number
- NCT02234089
- Locations
- 🇩🇪
Investigational site (there may be other sites in this country), Rottweil, Germany
Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT02229253
- Locations
- 🇳🇱
Groene Hart Ziekenhuis (there may be other sites in this country), Gouda, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.